Last reviewed · How we verify

NCT03498261

A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty

Active, enrolled Phase 1 Last updated 11 August 2025
What this trial tests

Phase 1 trial testing Gabapentin in Pain, Postoperative in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 January 2018
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorOhio State University
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingdouble
Primary purposeprevention
Enrollment50
Start date30 January 2018
Primary completion30 December 2025
Estimated completion30 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ohio State University

Who can join

18 and older, any sex, with Pain, Postoperative or Opioid Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adding a single preoperative dose of gabapentin to the standard pain regimen will reduce postoperative opioid consumption within the first 72 hours in patients undergoing rhinoplasty.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Gabapentin

Trials testing the same drug.

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

Other Ohio State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03498261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing